Guidelines & Consensus
Advances in Cervical Cancer Management: Biosensors, Nanotechnology, and AI Integration
Tawfeek et alDrug Development and Industrial Pharmacy
Cervical cancer remains a leading cause of morbidity and mortality among women worldwide, disproportionately impacting low- and middle-income nations facing restricted access to screening programs, human papillomavirus (HPV) vaccination, and advanced therapeutics. Comprehensive clinical reviews highlight the evolving management landscape across molecular pathology, diagnostics, and targeted therapies.\n\nRecent technological developments are addressing critical diagnostic barriers. Biosensor platforms are emerging for early disease identification to circumvent the technical constraints of conventional immunohistochemistry and biochemical assays. Concurrently, therapeutic vaccines represent an emerging alternative to traditional pharmacological and surgical approaches for cervical cancer prevention and treatment. Nanotechnology and targeted drug delivery systems are also finding active applications across oncologic diagnostics, tumor management, and HPV vaccine administration.\n\nIn clinical workflow optimization, artificial intelligence models show application in the early detection of HPV infections and in preoperative planning via AI-enhanced robotic surgical systems. Combining precision medicine, liquid biopsy, advanced screening tools, and global public health efforts remains essential for improving early detection and driving disease elimination.
Key Takeaways
- Biosensor technologies overcome the diagnostic limitations of conventional immunohistochemistry and biochemical-based assays for early cervical cancer detection.
Read the original sourceDrug Development and Industrial Pharmacy
